Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK

作者: Carolin Tonus

DOI: 10.3748/WJG.V12.I43.7007

关键词:

摘要: AIM: To evaluate the utility of innovative fecal tumor M2-Pyruvate kinase (M2-PK) test in our daily clinical routine, as a marker for pre-selection patients who should subsequently undergo colonoscopy diagnosis or exclusion colorectal cancer. METHODS: Fecal M2-PK was measured stool samples 96 study participants (33 with cancer, 21 rectal carcinoma and 42 controls) all underwent total colonoscopy. RESULTS: In 39 individuals control group, below 4.0 kU/L (93% specifi city). Colorectal tumors were accompanied by highly significant increase (P < 0.001) M2- PK levels (median: colon carcinoma, 23.1 kU/L; 6.9 14.7 kU/L), which correlated Duke's staging T-classifi cation. The overall sensitivity 78% increasing from 60% stage T1 to 100% T4 A 90% D tumors. CONCLUSION: is an appropriately sensitive tool pre-select those requiring further diagnostic confirmation

参考文章(35)
E Eigenbrodt, M Reinacher, R Friis, U Scheefers-Borchel, H Scheefers, Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Critical Reviews in Oncogenesis. ,vol. 3, pp. 91- 115 ,(1992)
Bo Zhang, Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls World Journal of Gastroenterology. ,vol. 10, pp. 1643- 1646 ,(2004) , 10.3748/WJG.V10.I11.1643
C Akrivakis, R Geppert, J Mesterharm, K Possinger, K D Wernecke, D Lüftner, P E Petrides, Tumor type M2 pyruvate kinase expression in advanced breast cancer Anticancer Research. ,vol. 20, pp. 5077- 5082 ,(2000)
David A Lieberman, William V Harford, Dennis J Ahnen, Dawn Provenzale, Stephen J Sontag, Thomas G Schnell, Gregorio Chejfec, Donald R Campbell, Theodore E Durbin, John H Bond, Douglas B Nelson, Stephen L Ewing, George Triadafilopoulos, Francisco C Ramirez, John G Lee, Judith F Collins, M Brian Fennerty, Tiina K Johnston, Christopher L Corless, Kenneth R McQuaid, Harinder Garewal, Richard E Sampliner, Thomas G Morales, Ronnie Fass, Robert E Smith, Yogesh Maheshwari, David G Weiss, None, One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. The New England Journal of Medicine. ,vol. 345, pp. 555- 560 ,(2001) , 10.1056/NEJMOA010328
T MORIKAWA, J KATO, Y YAMAJI, R WADA, T MITSUSHIMA, Y SHIRATORI, A Comparison of the Immunochemical Fecal Occult Blood Test and Total Colonoscopy in the Asymptomatic Population Gastroenterology. ,vol. 129, pp. 422- 428 ,(2005) , 10.1016/J.GASTRO.2005.05.056
M Naumann, B Schaum, G M Oremek, E Hanisch, W Rösch, J Mössner, W F Caspary, J Stein, [Faecal pyruvate kinase type M2--a valid screening parameter for colorectal cancer? Preliminary results from a multicenter comparative study]. Deutsche Medizinische Wochenschrift. ,vol. 129, pp. 1806- 1807 ,(2004) , 10.1055/S-2004-829033
Hiroshi Morikawa, Ken Toshina, Mitsuyuki Murano, Keiichi Hashimoto, Yoshihito Nakagawa, Osamu Saitoh, Kazuo Uchida, Kenichi Katsu, Takashi Nishikawa, Kentaro Maemura, Ichiro Hirata, Ryouichi Matsuse, A simple method of detecting K-ras point mutations in stool samples for colorectal cancer screening using one-step polymerase chain reaction/restriction fragment length polymorphism analysis. Clinica Chimica Acta. ,vol. 318, pp. 107- 112 ,(2002) , 10.1016/S0009-8981(01)00806-3